Recent Finacing
Recent Raise
Gracell Biotechnologies is a clinical-stage cell therapy company developing autologous FasTCAR (22–36h manufacturing) and TruUCAR off-the-shelf allogeneic CAR‑T platforms for hematologic malignancies and solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Gracell Biotechnologies.
